Genmab A/S (GMAB) Earnings History
Earnings Pressure24 years of earnings data (2002–2025) · 5-year EPS trend is negative
Loading earnings history...
Genmab A/S (GMAB) Earnings Overview
As of June 22, 2026, Genmab A/S (GMAB) reported trailing twelve-month net income of $2.61B, reflecting -87.3% year-over-year growth. The company earned $4.09 per diluted share over the past four quarters, with a net profit margin of 25.9%.
Looking at the long-term picture, GMAB's 5-year EPS compound annual growth rate (CAGR) stands at -26.6%, signaling declining earnings. The company achieved its highest annual net income of $7.84B in fiscal 2024.
Genmab A/S maintains industry-leading profitability with a gross margin of 91.7%, operating margin of 33.6%, and net margin of 25.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), SRPT ($65M net income, -32.5% margin), INCY ($1.43B net income, 25.0% margin), GMAB has room to improve margins relative to the peer group. Compare GMAB vs REGN →
GMAB Earnings vs Peers
Earnings metrics vs comparable public companies
GMAB Historical Earnings Data (2002–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $964M | -87.7% | $1.25B | $1.54 | 25.9% | 33.6% |
| 2024 | $7.84B | +80.2% | $6.70B | $12.14 | 36.4% | 31.1% |
| 2023 | $4.35B | -20.2% | $5.32B | $6.60 | 26.4% | 32.3% |
| 2022 | $5.45B | +84.4% | $6.27B | $8.26 | 37.6% | 43.2% |
| 2021 | $2.96B | -37.9% | $2.95B | $4.48 | 35.1% | 35.1% |
| 2020 | $4.76B | +119.7% | $6.31B | $7.22 | 47.1% | 62.4% |
| 2019 | $2.17B | +47.1% | $2.64B | $3.40 | 40.4% | 49.2% |
| 2018 | $1.47B | +33.4% | $1.38B | $2.37 | 48.7% | 45.6% |
| 2017 | $1.10B | -7.0% | $1.34B | $1.78 | 46.7% | 56.8% |
| 2016 | $1.19B | +55.5% | $1.05B | $1.92 | 65.4% | 58.0% |
| 2015 | $764M | +153.4% | $730M | $1.26 | 67.4% | 64.5% |
| 2014 | $301M | +168.1% | $265M | $0.53 | 35.4% | 31.2% |
| 2013 | $112M | +123.1% | $69M | $0.22 | 16.9% | 10.4% |
| 2012 | -$487M | +18.3% | -$117M | $-1.06 | -100.5% | -24.1% |
| 2011 | -$596M | -85.5% | -$249M | $-1.33 | -169.9% | -71.1% |
| 2010 | -$321M | +68.2% | -$161M | $-0.72 | -55.2% | -27.6% |
| 2009 | -$1.01B | -4.7% | -$498M | $-2.25 | -172.5% | -85.0% |
| 2008 | -$965M | -151.7% | -$722M | $-2.16 | -129.5% | -96.9% |
| 2007 | -$383M | +12.5% | -$437M | $-0.87 | -72.4% | -82.6% |
| 2006 | -$438M | -11.3% | -$472M | $-1.13 | -323.3% | -348.4% |
| 2005 | -$394M | +5.2% | -$428M | $-1.26 | -399.6% | -434.4% |
| 2004 | -$415M | -26.9% | $441M | $-1.57 | -10124.7% | 10760.1% |
| 2003 | -$327M | +31.8% | $342M | $-1.43 | -478.8% | 500.8% |
| 2002 | -$479M | - | -$483M | $-2.15 | - | - |
Download Data
Export GMAB earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into GMAB consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
What is GMAB earnings per share (EPS)?
GMAB trailing twelve-month (TTM) diluted EPS is $4.09, reflecting -87.3% year-over-year growth. The 5-year EPS CAGR is -26.6%. Complete EPS history from 2002 to 2025 is available in the table on this page.
What is Genmab A/S's net income?
Genmab A/S (GMAB) trailing twelve-month net income is $2.6B as of 2025. Earnings declined -87.3% year-over-year. Genmab A/S has been profitable for 13 consecutive years.
Is GMAB profitable?
Yes, GMAB is profitable with a TTM net income of $2.6B and a net profit margin of +25.9%. Genmab A/S has generated profits for 13 consecutive years.
What is GMAB's earnings growth rate?
GMAB compound annual EPS growth rates (CAGR): 1-Year: -87.3%, 3-Year: -42.9%, 5-Year: -26.6%, 10-Year: +2.0%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2002 to 2025.
What are GMAB's profit margins?
Genmab A/S net profit margin is +25.9%, operating margin is +33.6%, and gross margin is +91.7%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +4.5%.
Is GMAB growing earnings?
GMAB earnings are declining — EPS fell -87.3% year-over-year. TTM net income dropped to $2.6B. This contrasts with the 5-year CAGR of -26.6%.
What was GMAB's best earnings year?
Genmab A/S's highest annual net income on record is $7.8B, achieved in fiscal year 2024. Earnings history on this page spans 2002 to 2025 and includes all annual and quarterly figures.
What were GMAB's earnings last quarter?
GMAB's most recent reported quarter was Q1 2026. Net income was $53M with diluted EPS of $0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.